Although there are still at least three years of research for a dengue vaccine for the first time an experimental vaccine achieved an efficiency of 30.2% for three of the four serotypes of the virus.
The clinical trial of the vaccine-CYD TDV, of the Sanofi-Pasteur laboratory , in 4002 children aged between four and 12 years in Thailand, showed partial protection, but is hopeful for a disease without a vaccine that causes 50 to 100 million infections per year worldwide.
The report was published in the medical journal The Lancet.
“This study constitutes the first demonstration that a safe and effective vaccine against dengue, is possible. Research continues in several countries and our hope is to find better results in these larger studies, “he said, in a press release, Derek Wallace, representative of Sanofi-Pasteur laboratory .
The clinical trial of this vaccine candidate in phase II, phase in which enrolls a large number of human beings to see the effectiveness of the product.
However, not everyone sees this as encouraging news.
In a commentary accompanying the study in the journal Scott Halstead, of International Vaccine Institute in Seoul, said that even can not claim victory.
“This vaccine proved to be effective against serotype two and also would be effective only in mild infections of serotypes 1, 3 and 4, but not enough data to know how it would work in cases of severe infection,” he said.
Dengue is transmitted by mosquitoes Aedes aegypti and Aedes albopictus. Symptoms include fever and severe pain in joints and muscles. There may also be diarrhea, vomiting, nausea and bleeding in the nose and gums. If contracts more than once may result in dengue hemorrhagic fever and cause death .
In Costa Ricawere presented between 2009 and 2010 (the latter recorded 12,000 cases), the number of patients fell in 2011 and 2012. So far this year there have been 8229 cases and 517 hospitalizations.